Evidence map›Paper›PMID 26617406›Full record

ArticleEuropean journal of immunology2016

It is time to beelieve the CD1a hype!

Sai Harsha Krovi, Laurent Gapin

Open access · bronzeAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Sai Harsha KroviDepartment of Immunology and Microbiology, University of Colorado Anschutz Medical, Campus, Aurora, CO, USA.
Laurent GapinDepartment of Immunology and Microbiology, University of Colorado Anschutz Medical, Campus, Aurora, CO, USA.
University of Colorado Anschutz Medical Campus · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
iNKT Cell Recognition of Endogenous Lipid AntigensR01AI092108 · NIAID · UNIVERSITY OF COLORADO DENVER · PI GAPIN, LAURENT · 2011 to 2014
$1.5M
NCI NIH HHS P30 CA046934NCI NIH HHS P30CA046934NIAID NIH HHS AI092108NIAID NIH HHS R01 AI092108
6 · The paper itself

Abstract

Conventional T cells have historically been linked to exacerbating allergy. By efficiently generating primarily TH 2 cells, allergens skew the immune response to produce IL-4, IL-13, and IgE. Previously, CD1a-responsive T cells were shown to functionally respond to bee and wasp venom allergens. In this issue of the European Journal of Immunology, Subramaniam et al. [Eur. J. Immunol. 2016. 46: 242-252] show that more functionally active CD1a-restricted cells are present in bee venom-allergic patients than in healthy patients. Additionally, the authors show that these cells are not as frequently found in individuals receiving venom immunotherapy. Consequently, this study implicates CD1a-reactive cells as the primary responders to venom allergy, which considerably regulate the downstream immune response.

Indexed as

AnimalsBee VenomsFemaleHumansHypersensitivityMaleT-LymphocytesWasp VenomsBee VenomsWasp VenomsCD1aImmunotherapyT cellVenom allergy

Identifiers

PMID26617406
PMCPMC4758348
OpenAlexW2186737696

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.